SUNLENCA® (lenacapavir) Efficacy Data | HCP Site

SUNLENCA® Demonstrated Rapid and Long-acting Antiviral Activity¹

88% of participants taking SUNLENCA achieved a ≥0.5 log₁₀ copies/mL reduction in HIV-1 RNA after 14 days vs 17% of participants taking placebo^1,*

Click to view Study Design

Primary Endpoint: Proportion of Participants Achieving a ≥0.5 log₁₀ Decrease in Viral Load (Randomized Cohort) at Day 15^1,2

*In the randomized cohort (n=36).

Important Safety Information

Adverse reactions

Most common adverse reactions (incidence ≥3%, all grades) are injection site reactions (65%) and nausea (4%).

After 1 SC dose, 81% of participants taking SUNLENCA achieved virologic suppression at Week 26, and 83% of participants achieved virologic suppression at Week 52^1,†,‡

Secondary Endpoints: Weeks 26 and 52

View More Efficacy Data

Virologic Outcomes With SUNLENCA + Optimized Background Regimen
(Randomized Cohort)^1,§

Virologic Outcomes (HIV-1 RNA <50 copies/mL) at Week 52 With
SUNLENCA + Optimized Background Regimen (Randomized Cohort)^3,§

^†In the randomized cohort (n=36).

^‡In CAPELLA across cohorts 1 and 2, 79% of participants (57/72) received SUNLENCA 300 mg once every 7 days as oral bridging at some point during the 52-week treatment period.

86% of PARTICIPANTS were able to achieve HIV-1 RNA <200 copies/mL at Week 52 in the randomized cohort with SUNLENCA + OBR⁴

Click for Important Safety Information for SUNLENCA.

More participants whose OBR included ≥1 fully active ARV achieved virologic suppression at Week 52 when compared to those without any fully active agents¹

Virologic suppression (HIV-1 RNA <50/mL) with SUNLENCA by number of fully active agents in OBR:

≥2 fully active ARVs: 94% (n=15/16)
1 fully active ARV: 79% (n=11/14)
No fully active ARV: 67% (n=4/6)

ACHIEVING RAPID AND SUSTAINED SUPPRESSION is POSSIBLE with SUNLENCA¹

SEE HOW SUNLENCA IMPACTED CD4 COUNTS

INDICATION

SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations.

Important Safety Information

Contraindications

Coadministration: Concomitant administration of SUNLENCA is contraindicated with strong CYP3A inducers.

Warnings and precautions

Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported in patients treated with combination antiretroviral (ARV) therapy.

INDICATION

SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations.

Tap for Important Safety Information

Important Safety Information

Contraindications

Coadministration: Concomitant administration of SUNLENCA is contraindicated with strong CYP3A inducers.

Warnings and precautions

Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported in patients treated with combination antiretroviral (ARV) therapy.

INDICATION

SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations.

Long-acting properties and potential associated risks with SUNLENCA: Residual concentrations of SUNLENCA may remain in the systemic circulation of patients for up to 12 months or longer. SUNLENCA may increase exposure, and potential risk of adverse reactions, to drugs primarily metabolized by CYP3A initiated within 9 months after last injection. Counsel patients regarding the dosing schedule because nonadherence could lead to loss of virologic response and development of resistance. If virologic failure occurs, switch to an alternative regimen if possible. If discontinuing SUNLENCA, begin alternate suppressive ARV regimen within 28 weeks from last injection.
Injection site reactions may occur, and nodules and indurations may be persistent. Improper administration (intradermal injection) has been associated with serious injection site reactions.

Adverse reactions

Most common adverse reactions (incidence ≥3%, all grades) are injection site reactions (65%) and nausea (4%).

Drug interactions

Prescribing information: Consult the full prescribing information for SUNLENCA for more information on Contraindications, Warnings, and potentially significant drug interactions, including clinical comments.
Enzymes/transporters: Drugs that are strong or moderate inducers of CYP3A may significantly decrease the concentration of SUNLENCA. Drugs that strongly inhibit CYP3A, P-gp, and UGT1A1 together may significantly increase the concentration of SUNLENCA. SUNLENCA may increase the exposure of drugs primarily metabolized by CYP3A, when initiated within 9 months after the last injection of SUNLENCA, which may increase the potential risk of adverse reactions.

Dosage and administration

Dosage: Initiation with 1 of 2 options, followed by maintenance injection dosing once every 6 months. Tablets may be taken with or without food.
- Initiation Option 1: Day 1: 927 mg by subcutaneous injection and 600 mg orally (2 x 300-mg tablets). Day 2: 600 mg orally (2 x 300-mg tablets).
- Initiation Option 2: Day 1: 600 mg orally (2 x 300-mg tablets). Day 2: 600 mg orally (2 x 300-mg tablets). Day 8: 300 mg orally (1 x 300-mg tablet). Day 15: 927 mg by subcutaneous injection.
- Maintenance: 927 mg by subcutaneous injection every 26 weeks +/- 2 weeks from date of last injection.
Planned missed injections: If scheduled injection is to be missed by more than 2 weeks, SUNLENCA tablets may be used for oral bridging for up to 6 months until injections resume. Dosage is 300 mg orally (1 x 300-mg tablet) every 7 days.
Unplanned missed injections: During the maintenance period, if more than 28 weeks have elapsed since the last injection and tablets have not been taken for oral bridging, restart the initiation dosage regimen from Day 1, using Option 1 or Option 2, if clinically appropriate.

Pregnancy and lactation

Pregnancy: There is insufficient human data on the use of SUNLENCA during pregnancy. An Antiretroviral Pregnancy Registry (APR) has been established.
Lactation: Individuals with HIV-1 infection should be informed of the potential risks of breastfeeding.

Please see full Prescribing Information for SUNLENCA.